Drug intelligence / Profile preview

ADMVA

Development stage: Phase 1
Lead developer: IDT Biologika
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ADMVA is a multigenic HIV-1 candidate vaccine that utilizes a modified vaccinia Ankara (MVA) viral vector. It is designed to express five HIV-1 genes (gag, pol, DeltaV2env, tat, and nef) derived from a recombinant C/B' subtype of HIV-1. The vaccine aims to elicit both humoral (antibody) and cellular immune responses against these HIV-1 proteins, including gp120, to prevent HIV infection. It has been evaluated in Phase 1 clinical trials for safety and immunogenicity.

Targets

HIV-1 Pol polyproteinTat (HIV-1 Tat)Nef (HIV-1 Nef)Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on ADMVA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADMVA.

Explore the full profile